The Company is engaged in developing novel anticaner drugs, particularly hypoxia-activated prodrugs, small molecule targeted anticancer drugs and cell signaling pathway inhibitors. Since its inception, it has paid attention to protection of intellectual property rights and application of invention patents. In February 2012, the Company's first patent entitled “Synthesis methods of molecular targeted anticancer drug Crizotinib" was successfully submitted to State Intellectual Property Office of China. Since then, we have submitted 5 invention patent applications, and having more under the way.

Application or Invention No.	Name of Invention patents
201210038110.8	Synthesis methods of molecular targeted anticancer drug Crizotinib
201210211142.3	Development of anticancer o-nitro aromatic methoxy hypoxia-activated prodrugs based on Camptothecin
201210211145.7	Dvelopment of anticancer nitroaryl methoxy hypoxia-activated prodrugs based on Camptothecin
201210211151.2	Development of anticancer nitro aromatic methoxy hypoxia-activated prodrugs based on Camptothecin
201210334540.4	Synthesis of 3 - chloro-5 - amino pyridazine as medicinal and pesticide intermediates
201310608753.6	A novel synthesis route for molecular targeted anti-cancer drug crizotinib
201310608734.3	Development of an novel anticancer nitro aromatic methoxy hypoxia-activated prodrug based on crizotinib